[1] Global Initiative for Asthma. Global strategy for asthma management and prevention; 2019. Available at https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed at Jan 15th, 2020.
[2] Holgate ST, Wenzel S, Postma DS, et al. Asthma. Nat Rev Dis Primers 2015; 1: 15025. doi: 10.1038/nrdp.2015.25
[3] Lopes-Pacheco M, Robba C, Rocco PRM, et al. Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. Cell Biol Toxicol 2020, 36: 83-102. doi: 10.1007/s10565-019-09493-5.
[4] Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Rev Respir Med 2020; 14: 31-39. doi: 10.1080/17476348.2020.1679628.
[5] Suen CM, Stewart DJ, Montroy J, et al. Regenerative therapy for pulmonary arterial hypertension in animal models: a systematic review. Stem Cell Res Ther2019; 10: 75. doi: 10.1183/s13287-019-1172-6.
[6] Cruz FF, Borg ZD, Goodwin M, et al. CD11b+ and Sca-1+ cells exert the main beneficial effects of systemically administered bone marrow-derived mononuclear cells in a murine model of mixed Th2/Th17 allergic airway inflammation. Stem Cells Transl Med 2016; 5: 488-499. doi: 10.5966/sctm.2015-0141.
[7] Castro LL, Kitoko JZ, Xisto DG, et al. Multiple doses of adipose tissue-derived mesenchymal stromal cells induced immunosuppression in experimental asthma. Stem Cells Transl Med 2020; 9: 250-260. doi: 10.1002/sctm.19-0120.
[8] Abreu SC, Lopes-Pacheco M, da Silva AL, et al. Eicosapentaenoid acid enhances the effects of mesenchymal stromal cell therapy in experimental allergic asthma. Front Immunol 2018; 9: 1147. doi: 10.3389/fimmu.2018.01147.
[9] Lathrop MJ, Brooks EM, Bonenfant NR, et al. Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway. Stem Cells Transl Med 2014; 3: 194-205. doi: 10.5966/sctm.2013-0061.
[10] Abreu SC, Antunes MA, de Castro JC, et al. Bone marrow-derived mononuclear cells vs. mesenchymal stromal cells in experimental allergic asthma. Respir Physiol Neurobiol 2013; 187: 190-198. doi: 10.1016/j.resp.2013.03.014.
[11] Malaquias MAS, Oyama LA, Jericó PC, et al. Effects of mesenchymal stromal cells play a role the oxidant/antioxidant balance in a murine model of asthma. Allergol Immunopathol (Madr) 2018; 46: 136-143. doi: 10.1016/j.aller.2017.06.003.
[12] Morales MM, Souza SA, Loivos LP, et al. Pilot safety study of intrabronchial instillation of bone marrow-derived mononuclear cells in patients with silicosis. BMC Pulm Med 2015; 15: 66. doi: 10.1186/s12890-015-0061-8.
[13] Barbosa da Fonseca LM, Gutfilen B, Rosado de Castro PH, et al. Migration and homing of bone-marrow mononuclear cells in chronic ischemic stroke after intra-arterial injection. Exp Neurol 2010; 221: 122-128. doi: 10.1016/j.expneurol.2009.10.010.
[14] Martino HF, Oliveira OS, Souza FC, et al. A safety and feasibility study of cell therapy in dilated cardiomyopathy. Braz J Med Biol Res 2010; 43: 989-995. doi: 10.1590/s0100-879x2010007500093.
[15] Ohno Y, Hatabu H, Higashino T, et al. Dynamic perfusion MRI versus perfusion scintigraphy: prediction of postoperative lung function in patients with lung cancer. AJR Am J Roentgenol 2004; 182: 73-78. doi: 10.2214/ajr.182.1.1820073.
[16] Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327. doi: 10.1164/ajrccm/145.6.1321
[17] Lopes-Pacheco M, Ventura TG, de Oliveira HD, et al. Infusion of bone marrow mononuclear cells reduces lung fibrosis but not inflammation in the late stages of murine silicosis. PLoS One 2014; 9: e109982. doi: 10.1371/journal.pone.0109982.
[18] de Oliveira HD, de Melo EBB, Silva JD, et al. Therapeutic effects of bone marrow-derived mononuclear cells from healthy or silicotic donors on recipient silicosis mice. Stem Cell Res Ther 2017; 8: 259. doi: 10.1186/s13287-017-0699-7.
[19] Suda S, Yang B, Schaar K, et al. Autologous bone marrow mononuclear cells exert broad effects on short- and long-term biological and functional outcomes in rodents with intracerebral hemorrhage. Stem Cells Dev 2015; 24: 2756-2766. doi: 10.1089/scd.2015.0107.
[20] Silva JD, Lopes-Pacheco M, de Castro LL, et al. Eicosapentaenoic acid potentiates the therapeutic effects of adipose tissue-derived mesenchymal stromal cells on lung and distal organ injury in experimental sepsis. Stem Cell Res Ther 2019; 10: 264. doi: 10.1186/s13287-019-1365-z.
[21] Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009; 18: 683-692. doi: 10.1089/scd.2008.0253.
[22] Lopes-Pacheco M, Xisto DG, Ornellas FM, et al. Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis. Cell Physiol Biochem 2013; 32: 1681-1694. doi: 10.1159/000356603.
[23] Poggio HA, Antunes MA, Rocha NN, et al. Impact of one versus two doses of mesenchymal stromal cells on lung and cardiovascular repair in experimental emphysema. Stem Cell Res Ther 2018; 9: 296. doi: 10.1186/s13287-018-1043-6.
[24] Barbosa da Fonseca LM, Xavier SS, Rosado de Castro PH, et al. Biodistribution of bone marrow mononuclear cells in chronic chagasic cardiomyopathy after intracoronary injection. Int J Cardiol 2011; 149; 310-314. doi: 10.1016/j.ijcard.2010.02.008.
[25] Rosado-de-Castro PH, Pimentel-Coelho PM, Gutfilen B, et al. Radiopharmaceutical stem cell tracking for neurological diseases. Biomed Res Int 2014; 417091. doi: 10.115/2014/417091.